Galderma Group AG Logo

Galderma Group AG

A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.

GALD | SW

Overview

Corporate Details

ISIN(s):
CH1335392721
LEI:
89450001OK6O8ELQ4584
Country:
Switzerland
Address:
Zählerweg 10, 6300 Zug
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galderma Group AG is a pure-play pharmaceutical company specializing in dermatology. It operates across the full spectrum of skin health through three main business units: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. The company develops and markets an innovative, science-based portfolio of premium brands and treatments designed to meet the individual needs of both consumers and patients. Galderma is focused on providing solutions for a wide range of dermatological conditions, positioning itself as a leader solely dedicated to advancing skin health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Galderma Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Galderma Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-31 N/A Non-Executive member Sell None 935,664.75 CHF
2025-03-28 N/A Non-Executive member Sell None 1,876,958.07 CHF
2025-03-27 N/A Non-Executive member Sell None 265,440.84 CHF
2025-03-26 N/A Non-Executive member Sell None 673,175.70 CHF
2025-03-25 N/A Executive member Buy None 243,205.38 CHF
2025-03-20 N/A Non-Executive member Sell None 1,156,106.24 CHF
2025-03-20 N/A Non-Executive member Sell None 47,702.12 CHF
2025-03-17 N/A Executive member Sell None 7,962,599.99 CHF
2024-12-20 N/A Non-Executive member Sell None 105,831.00 CHF
2024-11-06 N/A Non-Executive member Sell None 177,500.00 CHF

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.